Table 2.
Characterization of the 124-E17/SP66 Discordant DLBCL Cases.
| BCL2 Discordanta n (%) |
BCL2 (−)Concordant n (%) |
BCL2 (+)Concordant n (%) |
Pb | |
|---|---|---|---|---|
| DLBCL, all subtypes (n=94) | 44 (46.8) | 18 (19.1) | 32 (34.1) | |
| BCL2gene status | (n=39) | (n=12) | (n=27) | |
| Translocation (+) | 4 (10.3) | 1 (8.3) | 9 (33.3) | |
| Amplification (+) | 17 (43.6) | 1 (8.3) | 10 (37.0) | |
| Chrs. 18 polysomy (+) | 3 (7.7) | 2 (16.7) | 1 (3.7) | |
| > 1 chromosomal abnormality | 22 (56.4) | 4 (33.3) | 16 (59.3) | |
| BCL2 phophorylation status | ||||
| Phospho-T69 (+) (n=37; 8; 25) | 13 (35.1) | 0 (0.0) | 5 (20.0) | 0.030 |
| Phospho-S70 (+) (n=27; 8; 20) | 13 (48.1) | 3 (37.5) | 9 (45.0) | 0.789 |
| Dual site (n=27; 8; 19) | 3 (11.1) | 0 (0.0) | 4 (21.1) | 1.000 |
| Single site (n=27; 8; 19) | 23 (85.2) | 3 (37.5) | 10 (52.6) | 0.008 |
a
defined as BCL2 (−) with 124 and BCL2 (+) with E17 and/or SP66
b
P-value only calculated for BCL2 phosphorylation status as the other variables are not directly compared for significance testing. Concordant (−) and (+) cases were pooled to form one collective group for statistical analysis to compare concordant and discordant cases.